MSI2 and cancer: Considering the golden standard in defining a drug’s putative target is that the depletion of a target confers resistance to the drug (Kapoor and Miller, 2017); it is essential to identify small molecules specifically sensitive to the wild-type (WT) but not MSI2-depleted cancer cells.